NCT05359861 2026-03-18
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Completed
Clinical Trials
240 trialsNCT05432492 2026-03-04
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Akeso
Phase 2 Completed
NCT03463876 2026-02-17
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03713593 2026-02-05
LEAP-002
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03867084 2026-02-04
KEYNOTE-937
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05641896 2026-01-22
18F-FAPI-74 GI
SOFIE
Phase 2 Completed
NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05908786 2025-12-11
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 1/2 Completed
NCT04374877 2025-11-10
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Completed
NCT05091346 2025-10-24
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT03412773 2025-10-14
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
BeiGene
Phase 3 Completed
NCT03062358 2025-09-30
MK-3475-394
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06230328 2025-09-29
BRA-HEP
AstraZeneca
Completed
NCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
NCT04487067 2025-09-22
AMETHISTA
Hoffmann-La Roche
Phase 3 Completed
NCT06358001 2025-09-22
EchoTip AcuCore Post-Market Clinical Study
Cook Group Incorporated
Completed
NCT06620510 2025-08-15
Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea
GC Cell Corporation
Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04242199 2025-07-14
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Completed
NCT04580485 2025-07-11
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
Phase 1 Completed
NCT03781934 2025-07-01
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
Medivir
Phase 1/2 Completed
NCT04696055 2025-05-13
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
Phase 2 Completed
NCT03783871 2025-04-25
NW
Ethicon, Inc.
Phase NA Completed
NCT04000737 2025-04-13
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
Yiviva Inc.
Phase 2 Completed
NCT06345001 2025-04-13
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
Bayer
Phase 1 Completed
NCT04943900 2025-04-09
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT06797427 2025-03-17
A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers
Disruptive Pharma
Phase EARLY_PHASE1 Completed
NCT04401800 2025-03-10
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
BeiGene
Phase 2 Completed
NCT04710641 2025-03-06
OUTREACH2
Mina Alpha Limited
Phase 2 Completed
NCT05233098 2025-03-06
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
Boston Scientific Corporation
Completed
NCT05227261 2025-02-18
K-DETEK
Gene Solutions
Completed
NCT02576509 2025-02-17
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb
Phase 3 Completed
NCT02421185 2025-02-03
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT05848947 2025-01-29
MAApping
Sirtex Medical
Phase 4 Completed
NCT04338685 2024-12-09
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Hoffmann-La Roche
Phase 1 Completed
NCT04926376 2024-11-29
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)
ABK Biomedical
Phase NA Completed
NCT03474640 2024-11-22
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
TopAlliance Biosciences
Phase 1 Completed
NCT03606590 2024-11-14
Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)
NovoCure Ltd.
Phase 2 Completed
NCT04313868 2024-11-06
GEN2
GenVivo, Inc.
Phase 1 Completed
NCT03419897 2024-10-26
Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
BeiGene
Phase 2 Completed
NCT03941873 2024-10-26
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
BeiGene
Phase 1/2 Completed
NCT01686607 2024-10-21
MYCOS
Astellas Pharma Inc
Completed
NCT02325739 2024-10-21
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Novartis
Phase 1/2 Completed
NCT02702414 2024-09-04
KEYNOTE-224
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02112656 2024-08-20
OPTIMA
Imunon
Phase 3 Completed
NCT02509507 2024-08-06
MASTERKEY-318
Amgen
Phase 1/2 Completed
NCT05053412 2024-08-02
HEPATIC
Helio Genomics
Completed
NCT03586050 2024-07-24
Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma in Korea
Ethicon, Inc.
Phase NA Completed
NCT03483922 2024-07-05
HCC Screening Using DNA Methylation Changes in ctDNA
HKGepitherapeutics
Completed